MiMedx Group Inc

Latest MiMedx Group Inc News and Updates

  • uploads///Part  Graph
    Company & Industry Overviews

    How Did Ziopharm Keep XBI from Losing More Ground?

    Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.

    By Peter Neil
  • uploads///GMED analysts reco
    Company & Industry Overviews

    Analyst Ratings for Globus Medical and Its Peers in February

    Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold.”

    By Kenneth Smith
  • uploads///MDXG EPS Trend
    Company & Industry Overviews

    Behind MiMedx Group’s Recent Financial Performance

    In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.

    By Kenneth Smith
  • uploads///pain injection market
    Company & Industry Overviews

    Why the Physician Office Pain Management Market Matters to MiMedx

    Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.

    By Kenneth Smith
  • uploads///MDXG _revenue growth
    Company & Industry Overviews

    Understanding MiMedx Group’s Zealous Focus on Sales

    MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.

    By Kenneth Smith
  • uploads///MDXGanalysts Reco
    Company & Industry Overviews

    MiMedx Group on the Street: Analyst Recommendations in January

    Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.

    By Kenneth Smith
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.